Why Biotech Has Become a Magnet for Investors
|09/28/2016||Posted by BusinessMediaguide.Com under General World News||
This week, a tiny company called Tobira made headlines for its enormously profitable acquisition by pharmaceutical giant, Allergan. In this deal, Allergan will make an upfront payment of $28.35 per share in cash and up to $49.84 per share in Contingent Value Rights (CVRs). Based on their contract, Tobira could receive up to $1.695 billion for the two drugs the company has developed to treat NASH disease.